- Home
- FRD vs MOLN Comparison
FRD vs MOLN Comparison
Compare FRD & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRD | MOLN |
|---|---|---|
| Founded | 1965 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 144.0M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FRD | MOLN |
|---|---|---|
| Price | $20.64 | $4.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 22.4K | 2.8K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | $14.02 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $14.52 | $3.41 |
| 52 Week High | $24.37 | $5.36 |
Technical Indicators
Market Signals| Indicator | FRD | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 52.87 |
| Support Level | $20.54 | $4.04 |
| Resistance Level | $22.76 | $4.51 |
| Average True Range (ATR) | 1.01 | 0.14 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 33.39 | 69.41 |
Price Performance
Historical ComparisonAbout FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.